Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$4.78 - $7.96 $194,068 - $323,176
-40,600 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$5.49 - $9.36 $20,955 - $35,727
-3,817 Reduced 8.59%
40,600 $233,000
Q4 2020

Feb 02, 2021

BUY
$8.13 - $12.79 $23,715 - $37,308
2,917 Added 7.03%
44,417 $397,000
Q3 2020

Nov 05, 2020

BUY
$11.64 - $16.3 $15,132 - $21,190
1,300 Added 3.23%
41,500 $483,000
Q2 2020

Aug 12, 2020

BUY
$5.38 - $16.14 $160,684 - $482,053
29,867 Added 289.04%
40,200 $644,000
Q1 2020

May 12, 2020

BUY
$4.2 - $13.0 $43,398 - $134,329
10,333 New
10,333 $62,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.